Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
25 April 2018 Photo Oteng Mpete
UFS and Medtronic collaboration set to enhance cardiac
From the left: Zampieri Luigi: Medtronic; Dania Choucair: Medtronic; Peter Fuller: Medtronic; Prof Francis Petersen: UFS Rector and Vice-Chancellor; Prof Gert van Zyl:Dean of the Faculty of Health Sciences, and Eline Visser: Medtronic.
A new Cardiac Simulation laboratory will be opened and hosted within the School of Biomedical Sciences’ Clinical Simulation and Skills Unit, at the University of the Free State’s Bloemfontein Campus. The new laboratory is a result of a partnership between Medtronic and UFS. 

The new laboratory will be used to enhance training for cardiothoracic, cardiology, vascular surgery, anaesthesiology and multiprofessional teams   such as doctors, nurses and allied health professionals. The establishment of the laboratory will be made possible by the generous provision of equipment for the establishment and operation of the Cardiac Simulation laboratory by Medtronic.  

Prioritising of patients at the heart of collaboration 
The development of a Cardiac Simulation laboratory at the UFS will not only benefit the training of specialists in various fields of specialisation but will also improve patient safety and reduce complication and mortality rates. The UFS is proud to be part of this initiative to train healthcare professionals to the benefit of the patients.

The Medtronic and UFS contract signing was attended by key stakeholders who included Prof Francis Smit: Head of Cardiothoracic Surgery; Prof Mathys Labuschagne: Head of the Clinical Simulation and Skills Unit; Prof Gert van Zyl: UFS Dean of the Faculty of Health Sciences and Prof Francis Petersen: UFS Rector and Vice-Chancellor. In attendance from Medtronic were Dania Choucair: Medtronic Director Clinical Research and Medical Education; Peter Fuller: Medtronic Country Director; Zampieri Luigi: Business Director   Cardiovascular Group; and Eline Visser: Business Manager   Structural Heart.

The Cardiac Simulation laboratory will make use of part task trainers, medium- and high- fidelity simulation as well as virtual-reality simulation to develop integrated interdisciplinary simulation programmes. These programmes are essential for proficiency development through deliberate practice and should become a statutory requirement for future trainees.

Objective and improved quality of training  
Standard cardiothoracic surgical training programmes are still based on the apprentice model. It implies that registrars in all programmes will attain surgical competency in addition to theoretical training fulfilling minimum statutory requirements for licensing and independent practice. It is highly dependent on surgical volumes, attitude of trainers and perceived surgical ability of the trainee. At best, it produces a mixed bag of competency levels. 

Well-designed integrated interdisciplinary simulation programmes offer an alternative that allows for deliberate practice in an organised step-wise progression model, with inbuilt assessment and feedback systems. This allows for proficiency training rather than competency training in which clear objectives can be met.

The UFS cardiothoracic programme is being designed as a hub and spoke model for South Africa and sub-Saharan Africa, combining distance learning with an onsite high-fidelity simulation and assessment centre. Off-site training in crew resource management or CRM (which addresses communication, decision-making, team-building and maintenance, workload management and situational awareness management), educational theory, surgical theory and basic bench model simulation will be provided. 

Multidisciplinary streams of knowledge 
According to Profs Francis Smit and Mathys Labuschagne, the role of simulation is a dynamic process of continuous movement between theory, simulation and clinical exposure.  “We strive to create an environment where there is free flow between these different components. Registrars and students come from different educational and cultural backgrounds in South Africa and Sub-Saharan Africa and by allowing deliberate practice for students with different needs to practice in their own time is contributing tremendously to students’ individual outcomes and development in the specialty.” 

This dynamic fulfils the needs of students with different competency levels and previous clinical exposure. Debriefing and formative assessment per session are pre-requisites for attending high-fidelity and virtual-reality simulation sessions at the Cardiac Simulation laboratory, because this kind of feedback contributes to the clinical and surgical development as well as inter-professional collaboration of the trainees. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 
When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?
Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept